Get the Stockscreener App
31.39
0.25%
-0.08
After Hours:
31.39
Alkermes Plc stock is traded at $31.39, with a volume of 1.42M.
It is down -0.25% in the last 24 hours and up +10.26% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$31.47
Open:
$31.53
24h Volume:
1.42M
Relative Volume:
0.98
Market Cap:
$5.31B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
16.10
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-1.63%
1M Performance:
+10.26%
6M Performance:
+14.15%
1Y Performance:
+16.09%
1-Day Range:
$31.22
$31.62
1-Week Range:
$30.32
$31.97
52-Week Range:
$22.90
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
31.39 | 5.31B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 - GuruFocus.com
Alkermes Earnings: Critical Q4 Results and 2025 Roadmap Coming February 12 - StockTitan
FY2027 EPS Estimates for Alkermes Lifted by Leerink Partnrs - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Trading (ALKS) With Integrated Risk Controls - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) EVP Sells $3,234,421.90 in Stock - MarketBeat
Alkermes plc (NASDAQ:ALKS) Sees Large Decline in Short Interest - MarketBeat
BofA Adjusts Price Target on Alkermes Public to $33 From $31 -February 03, 2025 at 10:16 am EST - Marketscreener.com
FY2025 EPS Estimates for Alkermes Lowered by Leerink Partnrs - MarketBeat
Alkermes FY2027 EPS Forecast Increased by Leerink Partnrs - Defense World
FY2025 EPS Estimates for Alkermes Reduced by Leerink Partnrs - Defense World
Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Jefferies maintains Buy on Alkermes stock, target at $41 By Investing.com - Investing.com UK
Pacer Advisors Inc. Decreases Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes Wide Awake To Blockbuster Narcolepsy Market Potential - Citeline News & Insights
Alkermes Plc to Host Earnings Call - ACCESS Newswire
Alkermes (NASDAQ:ALKS) Trading Up 5.4%Still a Buy? - MarketBeat
(ALKS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
With nearly $1B in the bank, Alkermes is on the hunt for deals - The Business Journals
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 14.1% - MarketBeat
Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price - Simply Wall St
(ALKS) Proactive Strategies - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Holdings Trimmed by JPMorgan Chase & Co. - MarketBeat
FY2024 EPS Estimates for Alkermes Lowered by Zacks Research - Defense World
Zacks Research Reduces Earnings Estimates for Alkermes - MarketBeat
What is Zacks Research's Forecast for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc (NASDAQ:ALKS) Receives $36.00 Average PT from Brokerages - MarketBeat
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Alkermes to Report Third Quarter Financial Results on October 24, 2024 - Quantisnow
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)? - Yahoo Finance
Alkermes plc (NASDAQ:ALKS) Sees Large Decrease in Short Interest - MarketBeat
Principal Financial Group Inc. Has $24.57 Million Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
(ALKS) On The My Stocks Page - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Stake Boosted by Sanctuary Advisors LLC - MarketBeat
Expansion Therapeutics Names Elliot Ehrich, MD, Chief Medical Officer - Marketscreener.com
Alkermes pays off and terminates major credit agreement By Investing.com - Investing.com Canada
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
Alkermes pays off and terminates major credit agreement - Investing.com
Alkermes Prepares for New Flexibility Post Credit Termination - TipRanks
Tidal Investments LLC Takes Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Geode Capital Management LLC Sells 60,037 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt - Simply Wall St
Wilmington Savings Fund Society FSB Invests $582,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Barclays PLC Boosts Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes To Take Part In The Fourth Annual Evercore ISI Healthconx Conference - Environmental Expert
Opioid Use Disorder Market: Share, Key Trends, Growth Drivers, - openPR
When (ALKS) Moves Investors should Listen - Stock Traders Daily
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):